CORE 4- Small Animal Core

CORE 4-小动物核心

基本信息

批准号：
10625691
负责人：
Eric P Skaar
金额：
$ 18.26万
依托单位：
VANDERBILT UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-03-03 至 2028-02-29
项目状态：
未结题

项目摘要

SUMMARY-SMALL ANIMAL CORE A critical component of our vaccine development program is efficacy testing of candidate antigens in murine models of C. difficile infection. The Small Animal Core of our program will achieve this goal and identify lead antigens for the development of novel vaccines to prevent against CDI. The Small Animal Core will be led by Dr. Eric Skaar. The Skaar laboratory has significant experience in the murine model of C. difficile infection and has also developed a new live C. difficile vaccine model in mice as described in Project 2. In addition, the Skaar laboratory has experience testing the therapeutic efficacy of both small molecules and antibodies in murine models. This experience will be used to guide the creation of a Small Animal Core to test the efficacy of lead antigens developed by this program. The Small Animal Core will benefit from the expertise of the Translational Pathology Shared Resource (TPSR) which includes access to a board-certified veterinary pathologist with experience in in vivo modeling of human disease, including molecular pathology, toxicopathologic assessment, and digital pathology as well as advanced training in veterinary anatomic pathology and murine models. The Small Animal Core will receive optimized candidate antigens from Scientific Core 2. These proteins will be tested for efficacy in appropriate murine models of CDI. Candidate antigens will be tested alone or in combination. Combined, the efforts of the Small Animal Core will result in the identification of lead antigens for the development of novel vaccines that protect against infections caused by C. difficile.

摘要小动物核心我们的疫苗开发计划的关键组成部分是对鼠类候选抗原的功效测试艰难梭菌感染的模型。我们计划的小动物核心将实现这一目标并确定铅用于开发新型疫苗以防止CDI的抗原。小动物核心将由博士领导。埃里克·斯卡尔（Eric Skaar）。 Skaar实验室在艰难梭菌感染的鼠模型中具有丰富的经验，并且具有如项目2中所述，在小鼠中还开发了一种新的活梭菌疫苗模型。此外，Skaar 实验室具有测试小分子和抗体在鼠中的治疗功效的经验型号。这种经验将用于指导创建小动物核心以测试铅的功效该程序开发的抗原。小动物核心将受益于翻译的专业知识病理共享资源（TPSR），包括访问董事会认证的兽医病理学家人体疾病体内建模的经验，包括分子病理学，毒理病理评估，以及数字病理学以及兽医解剖病理学和鼠模型的高级培训。这小动物核心将从科学核心2接收优化的候选抗原。这些蛋白质将进行测试在适当的CDI鼠模型中有效。候选抗原将单独或组合进行测试。相结合，小动物核心的努力将导致铅抗原的发展防止艰难梭菌引起的感染的新型疫苗。